Published in Clin Cancer Res on October 01, 2007
A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature (2009) 18.39
An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell (2008) 5.47
Medulloblastomics: the end of the beginning. Nat Rev Cancer (2012) 3.01
A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions. Proc Natl Acad Sci U S A (2012) 2.85
Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res (2009) 2.54
Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts. Neuro Oncol (2009) 2.23
PVT1 dependence in cancer with MYC copy-number increase. Nature (2014) 2.13
MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J Exp Med (2012) 1.85
Identification of candidate growth promoting genes in ovarian cancer through integrated copy number and expression analysis. PLoS One (2010) 1.60
A functional variant at a prostate cancer predisposition locus at 8q24 is associated with PVT1 expression. PLoS Genet (2011) 1.60
Amplification of PVT-1 is involved in poor prognosis via apoptosis inhibition in colorectal cancers. Br J Cancer (2013) 1.58
Role of microRNA 1207-5P and its host gene, the long non-coding RNA Pvt1, as mediators of extracellular matrix accumulation in the kidney: implications for diabetic nephropathy. PLoS One (2013) 1.58
p53-Dependent induction of PVT1 and miR-1204. J Biol Chem (2011) 1.56
Genetic variants associated with increased risk of malignant pleural mesothelioma: a genome-wide association study. PLoS One (2013) 1.55
Genome profiling of ERBB2-amplified breast cancers. BMC Cancer (2010) 1.53
Copy number analysis identifies novel interactions between genomic loci in ovarian cancer. PLoS One (2010) 1.50
Analysis of long non-coding RNA expression profiles in gastric cancer. World J Gastroenterol (2013) 1.50
Expression and prognostic impact of lncRNAs in acute myeloid leukemia. Proc Natl Acad Sci U S A (2014) 1.35
High-resolution analysis of copy number alterations and associated expression changes in ovarian tumors. BMC Med Genomics (2009) 1.33
Long noncoding RNAs in development and cancer: potential biomarkers and therapeutic targets. Mol Cell Ther (2015) 1.32
The 8q24 gene desert: an oasis of non-coding transcriptional activity. Front Genet (2012) 1.28
Genome-wide identification of genes with amplification and/or fusion in small cell lung cancer. Genes Chromosomes Cancer (2013) 1.23
Functional annotation of colon cancer risk SNPs. Nat Commun (2014) 1.19
Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemia. J Exp Med (2010) 1.15
Computational analysis identifies a sponge interaction network between long non-coding RNAs and messenger RNAs in human breast cancer. BMC Syst Biol (2014) 1.14
The long non-coding RNA PCAT-1 promotes prostate cancer cell proliferation through cMyc. Neoplasia (2014) 1.11
PVT1: a rising star among oncogenic long noncoding RNAs. Biomed Res Int (2015) 1.10
Long noncoding RNA PVT1 indicates a poor prognosis of gastric cancer and promotes cell proliferation through epigenetically regulating p15 and p16. Mol Cancer (2015) 1.08
A miR-1207-5p binding site polymorphism abolishes regulation of HBEGF and is associated with disease severity in CFHR5 nephropathy. PLoS One (2012) 1.08
Transcription factor-microRNA-target gene networks associated with ovarian cancer survival and recurrence. PLoS One (2013) 1.06
Increased expression of the lncRNA PVT1 promotes tumorigenesis in non-small cell lung cancer. Int J Clin Exp Pathol (2014) 1.05
FMLNCSIM: fuzzy measure-based lncRNA functional similarity calculation model. Oncotarget (2016) 1.04
Long non-coding RNA PVT1 is associated with tumor progression and predicts recurrence in hepatocellular carcinoma patients. Oncol Lett (2014) 1.03
Functional characterization of the plasmacytoma variant translocation 1 gene (PVT1) in diabetic nephropathy. PLoS One (2011) 1.02
Tetracycline-inducible shRNA targeting long non-coding RNA PVT1 inhibits cell growth and induces apoptosis in bladder cancer cells. Oncotarget (2015) 0.99
Comprehensive analysis of long non-coding RNAs in ovarian cancer reveals global patterns and targeted DNA amplification. PLoS One (2013) 0.99
Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Hum Mutat (2012) 0.98
Role of non-coding RNAs in maintaining primary airway smooth muscle cells. Respir Res (2014) 0.95
Constructing lncRNA functional similarity network based on lncRNA-disease associations and disease semantic similarity. Sci Rep (2015) 0.95
Frequent coamplification and cooperation between C-MYC and PVT1 oncogenes promote malignant pleural mesothelioma. J Thorac Oncol (2014) 0.94
Discovery, Annotation, and Functional Analysis of Long Noncoding RNAs Controlling Cell-Cycle Gene Expression and Proliferation in Breast Cancer Cells. Mol Cell (2015) 0.94
Activation of multiple cancer pathways and tumor maintenance function of the 3q amplified oncogene FNDC3B. Cell Cycle (2012) 0.92
Evolutionary analysis across mammals reveals distinct classes of long non-coding RNAs. Genome Biol (2016) 0.90
Pan-cancer transcriptome analysis reveals long noncoding RNAs with conserved function. RNA Biol (2015) 0.90
Meta-analysis of 8q24 for seven cancers reveals a locus between NOV and ENPP2 associated with cancer development. BMC Med Genet (2011) 0.90
Gene Expression Differences between Enriched Normal and Chronic Myelogenous Leukemia Quiescent Stem/Progenitor Cells and Correlations with Biological Abnormalities. J Oncol (2011) 0.89
Long non-coding RNAs as prognostic markers in human breast cancer. Oncotarget (2016) 0.89
Long noncoding RNAs in diseases of aging. Biochim Biophys Acta (2015) 0.88
Long Non-Coding RNAs As Potential Novel Prognostic Biomarkers in Colorectal Cancer. Front Genet (2016) 0.87
Noncoding RNAs in DNA repair and genome integrity. Antioxid Redox Signal (2013) 0.86
Identification of candidate epigenetic biomarkers for ovarian cancer detection. Oncol Rep (2009) 0.85
Transcriptional profiling analysis and functional prediction of long noncoding RNAs in cancer. Oncotarget (2016) 0.85
Involvement of long non-coding RNA in colorectal cancer: From benchtop to bedside (Review). Oncol Lett (2015) 0.85
Breast cancer genomes--form and function. Curr Opin Genet Dev (2010) 0.85
Overexpression of long non-coding RNA PVT1 in ovarian cancer cells promotes cisplatin resistance by regulating apoptotic pathways. Int J Clin Exp Med (2015) 0.84
The Role of Long Non-Coding RNAs in Ovarian Cancer. Iran Biomed J (2016) 0.84
The Significance of Long Noncoding RNA H19 in Predicting Progression and Metastasis of Cancers: A Meta-Analysis. Biomed Res Int (2016) 0.83
Construction and analysis of lncRNA-lncRNA synergistic networks to reveal clinically relevant lncRNAs in cancer. Oncotarget (2015) 0.83
Long non-coding RNAs in haematological malignancies. Int J Mol Sci (2013) 0.83
Promoter Hypomethylation and Expression Is Conserved in Mouse Chronic Lymphocytic Leukemia Induced by Decreased or Inactivated Dnmt3a. Cell Rep (2016) 0.82
Emerging paradigms of long non-coding RNAs in gastrointestinal cancer. Am J Stem Cells (2014) 0.81
p27Kip1 mediates addiction of ovarian cancer cells to MYCC (c-MYC) and their dependence on MYC paralogs. J Biol Chem (2010) 0.81
Integrative analyses of transcriptome sequencing identify novel functional lncRNAs in esophageal squamous cell carcinoma. Oncogenesis (2017) 0.81
The lncRNA PVT1 Contributes to the Cervical Cancer Phenotype and Associates with Poor Patient Prognosis. PLoS One (2016) 0.81
An overview of long non-coding RNAs in ovarian cancers. Oncotarget (2016) 0.80
8q24 amplified segments involve novel fusion genes between NSMCE2 and long noncoding RNAs in acute myelogenous leukemia. J Hematol Oncol (2014) 0.80
Identification of senescence-associated circular RNAs (SAC-RNAs) reveals senescence suppressor CircPVT1. Nucleic Acids Res (2016) 0.79
LncRNA PVT1 regulates prostate cancer cell growth by inducing the methylation of miR-146a. Cancer Med (2016) 0.78
Downregulation of BC200 in ovarian cancer contributes to cancer cell proliferation and chemoresistance to carboplatin. Oncol Lett (2015) 0.78
PVT1 Exon 9: A Potential Biomarker of Aggressive Prostate Cancer? Int J Environ Res Public Health (2015) 0.78
Role of the long non-coding RNA PVT1 in the dysregulation of the ceRNA-ceRNA network in human breast cancer. PLoS One (2017) 0.78
Transcriptional profiling identifies the long noncoding RNA plasmacytoma variant translocation (PVT1) as a novel regulator of the asthmatic phenotype in human airway smooth muscle. J Allergy Clin Immunol (2016) 0.77
Biological function and mechanism of MALAT-1 in renal cell carcinoma proliferation and apoptosis: role of the MALAT-1-Livin protein interaction. J Physiol Sci (2016) 0.77
Integrative analysis reveals clinical phenotypes and oncogenic potentials of long non-coding RNAs across 15 cancer types. Oncotarget (2016) 0.77
Genetic variants in miRNA processing genes and pre-miRNAs are associated with the risk of chronic lymphocytic leukemia. PLoS One (2015) 0.77
LncRNA BCAR4 wires up signaling transduction in breast cancer. RNA Biol (2015) 0.77
The well-accepted notion that gene amplification contributes to increased expression still remains, after all these years, a reasonable but unproven assumption. J Carcinog (2016) 0.76
Long Noncoding RNA PVT1 as a Novel Diagnostic Biomarker and Therapeutic Target for Melanoma. Biomed Res Int (2017) 0.76
A Comprehensive Characterization of the Function of LincRNAs in Transcriptional Regulation Through Long-Range Chromatin Interactions. Sci Rep (2016) 0.76
Construction of differential mRNA-lncRNA crosstalk networks based on ceRNA hypothesis uncover key roles of lncRNAs implicated in esophageal squamous cell carcinoma. Oncotarget (2016) 0.75
Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. Int J Cancer (2016) 0.75
Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR. Sci Data (2016) 0.75
Cardiac hypertrophy is positively regulated by long non-coding RNA PVT1. Int J Clin Exp Pathol (2015) 0.75
Dysregulated Expression of Long Noncoding RNAs in Ovarian Cancer. Int J Gynecol Cancer (2016) 0.75
Dysregulated expression of long noncoding RNAs in gynecologic cancers. Mol Cancer (2017) 0.75
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet (2017) 0.75
LncRNAs expression profiling in normal ovary, benign ovarian cyst and malignant epithelial ovarian cancer. Sci Rep (2016) 0.75
Aberrant Promoter Hypomethylation in CLL: Does It Matter for Disease Development? Front Oncol (2016) 0.75
HMMR antisense RNA 1, a novel long noncoding RNA, regulates the progression of basal-like breast cancer cells. Breast Cancer (Dove Med Press) (2016) 0.75
LncSubpathway: a novel approach for identifying dysfunctional subpathways associated with risk lncRNAs by integrating lncRNA and mRNA expression profiles and pathway topologies. Oncotarget (2017) 0.75
Non-coding single nucleotide variants affecting estrogen receptor binding and activity. Genome Med (2016) 0.75
lncRNAs and MYC: An Intricate Relationship. Int J Mol Sci (2017) 0.75
Selective expression of long non-coding RNAs in a breast cancer cell progression model. J Cell Physiol (2017) 0.75
Kanglaite inhibits the expression of drug resistance genes through suppressing PVT1 in cisplatin-resistant gastric cancer cells. Exp Ther Med (2017) 0.75
The prognostic value of abnormally expressed lncRNAs in colorectal cancer: A meta-analysis. PLoS One (2017) 0.75
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res (2006) 18.44
Evolution of genes and genomes on the Drosophila phylogeny. Nature (2007) 18.01
Distinct sets of genetic alterations in melanoma. N Engl J Med (2005) 17.26
Use of proteomic patterns in serum to identify ovarian cancer. Lancet (2002) 16.38
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell (2006) 16.05
Integrated genomic characterization of endometrial carcinoma. Nature (2013) 14.29
ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med (2010) 13.07
Identification of functional elements and regulatory circuits by Drosophila modENCODE. Science (2010) 12.39
The developmental transcriptome of Drosophila melanogaster. Nature (2010) 11.85
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Discovery of functional elements in 12 Drosophila genomes using evolutionary signatures. Nature (2007) 11.66
Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov (2005) 11.46
The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet (2013) 11.29
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell (2007) 11.21
The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer (2009) 9.01
Systematic determination of patterns of gene expression during Drosophila embryogenesis. Genome Biol (2002) 8.89
Induction of tumors in mice by genomic hypomethylation. Science (2003) 8.86
An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res (2004) 8.86
Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med (2008) 8.77
Annotation of the Drosophila melanogaster euchromatic genome: a systematic review. Genome Biol (2002) 8.59
Exploiting transcription factor binding site clustering to identify cis-regulatory modules involved in pattern formation in the Drosophila genome. Proc Natl Acad Sci U S A (2002) 8.56
The BDGP gene disruption project: single transposon insertions associated with 40% of Drosophila genes. Genetics (2004) 8.40
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature (2012) 8.13
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res (2008) 8.12
Finishing a whole-genome shotgun: release 3 of the Drosophila melanogaster euchromatic genome sequence. Genome Biol (2002) 8.07
Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci U S A (2004) 7.96
Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther (2006) 7.73
End-sequence profiling: sequence-based analysis of aberrant genomes. Proc Natl Acad Sci U S A (2003) 7.70
Chromosome aberrations in solid tumors. Nat Genet (2003) 7.01
Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell (2012) 6.80
Tools for neuroanatomy and neurogenetics in Drosophila. Proc Natl Acad Sci U S A (2008) 6.35
Transcription factors bind thousands of active and inactive regions in the Drosophila blastoderm. PLoS Biol (2008) 6.30
Global analysis of patterns of gene expression during Drosophila embryogenesis. Genome Biol (2007) 6.27
The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol (2007) 6.22
Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med (2011) 6.15
A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med (2013) 6.09
miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med (2008) 5.91
The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol (2007) 5.81
The transposable elements of the Drosophila melanogaster euchromatin: a genomics perspective. Genome Biol (2002) 5.80
Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol (2012) 5.70
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res (2009) 5.68
Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med (2009) 5.63
Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol (2002) 5.52
Exploiting position effects and the gypsy retrovirus insulator to engineer precisely expressed transgenes. Nat Genet (2008) 5.50
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol (2008) 5.19
Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med (2008) 5.19
A prediction-based resampling method for estimating the number of clusters in a dataset. Genome Biol (2002) 5.15
Heterochromatic sequences in a Drosophila whole-genome shotgun assembly. Genome Biol (2002) 5.09
High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov (2011) 4.78
Revisiting the protein-coding gene catalog of Drosophila melanogaster using 12 fly genomes. Genome Res (2007) 4.73
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell (2009) 4.71
The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat Genet (2005) 4.70
The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med (2004) 4.69
Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J Biol Chem (2007) 4.60
A comparison study: applying segmentation to array CGH data for downstream analyses. Bioinformatics (2005) 4.57
Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci U S A (2011) 4.55
Drosophila DNase I footprint database: a systematic genome annotation of transcription factor binding sites in the fruitfly, Drosophila melanogaster. Bioinformatics (2004) 4.37
Translating insights from the cancer genome into clinical practice. Nature (2008) 4.37
A module of negative feedback regulators defines growth factor signaling. Nat Genet (2007) 4.35
In situ analyses of genome instability in breast cancer. Nat Genet (2004) 4.32
Derailed endocytosis: an emerging feature of cancer. Nat Rev Cancer (2008) 4.25
Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics (2005) 4.18
Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell (2006) 4.13
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med (2011) 4.10
Benchmarking tools for the alignment of functional noncoding DNA. BMC Bioinformatics (2004) 4.00
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep (2013) 3.85
Rab25 associates with alpha5beta1 integrin to promote invasive migration in 3D microenvironments. Dev Cell (2007) 3.84
Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res (2005) 3.80
Restriction of receptor movement alters cellular response: physical force sensing by EphA2. Science (2010) 3.72
Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci U S A (2008) 3.71
Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nat Genet (2003) 3.70